GlassScriptPhysician profile
Benjamin G Rueda
NPI 1891767786
$3,955.95
in general payments reported to CMS, 2019-2025
30 companies · $1,710 in 2025
The $1,710 reported for 2025 was more than what 92% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $477 · 2020: $464 · 2021: $151 · 2022: $170 · 2023: $513 · 2024: $471 · 2025: $1,710.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,912 · Travel and Lodging: $782.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,912.32 |
| Travel and Lodging | $782.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Heartflow, INC. | $1,076.16 | 2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $280.83 | 2019-2025 | Lifevest |
| E.R. Squibb & Sons, L.L.C. | $268.79 | 2019-2025 | Camzyos, Eliquis |
| Pfizer INC. | $259.81 | 2019-2025 | |
| Abbott Laboratories | $255.73 | 2019-2020 | |
| Edwards Lifesciences Corporation | $229.46 | 2020-2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv), Sapien 3 Ultra Resilia |
| Boston Scientific Corporation | $193.01 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $181.49 | 2019-2025 | |
| Amgen INC. | $138.83 | 2019-2025 | Repatha, Repatha |
| Merck Sharp & Dohme LLC | $136.72 | 2023-2025 | Verquvo |
| Janssen Pharmaceuticals, INC | $131.81 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $110.45 | 2019-2023 | Jardiance |
| Medtronic, INC. | $80.63 | 2022-2025 | Harmony |
| Cleerly, INC. | $63.69 | 2024 | Cleerly Labs, Cleerly Ischemia |
| Impulse Dynamics (USA) INC. | $53.45 | 2023-2024 | Optimizer, Optimizer |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotronik INC. | $48.79 | 2019 | |
| Kestra Medical Technology Services, INC. | $48.37 | 2024 | Assure Wcd |
| Bridgebio Pharma, INC. | $46.31 | 2025 | Attruby |
| Novo Nordisk INC | $44.27 | 2025 | Ozempic, Wegovy |
| Lexicon Pharmaceuticals, INC. | $43.87 | 2023-2024 | Inpefa |
| Astrazeneca Pharmaceuticals LP | $43.76 | 2021-2025 | Lokelma |
| Janssen Scientific Affairs, LLC | $39.61 | 2023-2024 | Xarelto |
| Amarin Pharma, INC. | $35.37 | 2019-2021 | |
| Scpharmaceuticals INC. | $31.25 | 2024-2025 | |
| Vifor Pharma, INC. | $28.80 | 2023 | Veltassa |
| Lundbeck LLC | $22.63 | 2019 | |
| Sanofi-Aventis U.S. LLC | $17.50 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $16.83 | 2019 | |
| Medtronic Vascular, INC. | $14.69 | 2020 | |
| Esperion Therapeutics, INC. | $13.04 | 2023 | Nexletol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Rueda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.